It all started with the mission to improve the life of at least one patient.
We’ve now lost count.
But our mission remains just as personal.
Behind every scan is a story
Many of us at icometrix have seen someone we love lose words, memories, or independence to a brain disorder.
That’s why our mission is personal.
A life interrupted, a family searching for answers, a care team trying to make the right call.
We build technology to bring clarity in those moments. To help clinicians see what matters, and to help patients hold on to who they are.
From university spin-off to global leaders
2011
icometrix was founded as a spin-off from two Belgian universities and hospitals
2015
Achieved CE marking for icobrain, unlocking commercialization across Europe
2016
First FDA clearance obtained, launching our US presence
2017
Expanded icobrain to multiple neurological conditions, including Alzheimer's, stroke, and traumatic brain injury
2018
Adopted by over 300 hospitals and major pharmaceutical partners worldwide
2021
Secured multiple patents for AI-driven medical imaging technologies
2023
icobrain is the first AI neuroradiology solution to receive U.S. reimbursement approval from the AMA based on its extensive validation
2024
icobrain aria became the only FDA-cleared CADe/CADx solution in neuroradiology - meeting the urgent need for ARIA monitoring in Alzheimer’s care
%20(11).png)
.jpg)
%20(9).png)
Meet the people who make all of this happen
.jpeg)
.jpeg)
